reboxetine has been researched along with doxepin in 2 studies
Studies (reboxetine) | Trials (reboxetine) | Recent Studies (post-2010) (reboxetine) | Studies (doxepin) | Trials (doxepin) | Recent Studies (post-2010) (doxepin) |
---|---|---|---|---|---|
626 | 193 | 184 | 885 | 207 | 129 |
Protein | Taxonomy | reboxetine (IC50) | doxepin (IC50) |
---|---|---|---|
5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.046 | |
Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 0.029 | |
Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 0.258 | |
Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.042 | |
5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.2 | |
Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.026 | |
Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.6675 | |
Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 0.077 | |
5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.2 | |
Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.0355 | |
Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.5145 | |
5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.8595 | |
Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.069 | |
D(1A) dopamine receptor | Homo sapiens (human) | 0.688 | |
Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 0.029 | |
Histamine H2 receptor | Homo sapiens (human) | 1.867 | |
Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.118 | |
5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.038 | |
5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.046 | |
5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.8595 | |
5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | 0.2 | |
5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | 0.2 | |
5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.2 | |
5-hydroxytryptamine receptor 6 | Rattus norvegicus (Norway rat) | 0.2 | |
Sodium-dependent serotonin transporter | Homo sapiens (human) | 0.042 | |
5-hydroxytryptamine receptor 7 | Rattus norvegicus (Norway rat) | 0.2 | |
5-hydroxytryptamine receptor 5A | Rattus norvegicus (Norway rat) | 0.2 | |
5-hydroxytryptamine receptor 5B | Rattus norvegicus (Norway rat) | 0.2 | |
Histamine H1 receptor | Homo sapiens (human) | 0.0006 | |
D(3) dopamine receptor | Homo sapiens (human) | 1.393 | |
5-hydroxytryptamine receptor 3A | Rattus norvegicus (Norway rat) | 0.2 | |
5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.089 | |
Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | 1.6 | |
5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 0.32 | |
5-hydroxytryptamine receptor 4 | Rattus norvegicus (Norway rat) | 0.2 | |
Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.631 | |
5-hydroxytryptamine receptor 3B | Rattus norvegicus (Norway rat) | 0.2 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bajbouj, M; Danker-Hopfe, H; Gallinat, J; Hellen, F; Lang, UE; Lisanby, SH; Neu, P; Vesper, J | 1 |
Jiao, Y; Liang, Y; Lin, J; Qu, H; Sun, Y; Xu, J; Zhao, C | 1 |
1 trial(s) available for reboxetine and doxepin
Article | Year |
---|---|
Motor cortex excitability after vagus nerve stimulation in major depression.
Topics: Adult; Benzodiazepines; Citalopram; Clomipramine; Clozapine; Depressive Disorder; Doxepin; Drug Therapy, Combination; Electric Stimulation; Female; Humans; Lamotrigine; Lithium Carbonate; Male; Mianserin; Middle Aged; Mirtazapine; Morpholines; Motor Cortex; Neural Conduction; Neural Inhibition; Olanzapine; Paroxetine; Psychiatric Status Rating Scales; Reboxetine; Tranylcypromine; Triazines; Vagus Nerve; Valproic Acid | 2007 |
1 other study(ies) available for reboxetine and doxepin
Article | Year |
---|---|
Comparative efficacy and acceptability of antidepressant treatment in poststroke depression: a multiple-treatments meta-analysis.
Topics: Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Depression; Depressive Disorder; Doxepin; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Morpholines; Paroxetine; Patient Acceptance of Health Care; Reboxetine; Selective Serotonin Reuptake Inhibitors; Stroke; Treatment Outcome | 2017 |